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Purpose: Malnutrition and chronic inflammation in dialysis patients negatively impacts 
  prognosis. However, intervening to correct this problem (through nutritional supplementation) 
is often hampered by poor compliance due to both medical and socioeconomic barriers. We have 
therefore performed a pilot study to investigate the technical feasibility of “directly observed 
treatment” of nutritional supplementation (protein and omega-3 fatty acids), administered 
during regular dialysis sessions. Secondary end points included observation of nutritional and 
inflammatory status of hypoalbuminemic patients undergoing hemodialysis.
Methods: Main inclusion criteria were serum albumin # 3.9 g/dL (3 months prior to the study). 
Sixty-three eligible patients agreed to participate. Two intervention groups received 30 mL of a 
liquid protein supplement plus either 2.4 g omega-3 (1800 mg eicosapentaenoic acid + 600 mg 
docosahexaenoic acid) or a placebo, three times per week after their routine dialysis session for 
6 months. Serum albumin, plasma lipids, and other indicators of nutritional and inflammatory 
status were measured.
Results: Directly observed nutritional supplementation resulted in a significant improvement 
in the low density lipoprotein cholesterol/high density lipoprotein cholesterol ratio in the 
omega-3 group as compared to the placebo group (P = 0.043). For the omega-3 group, serum 
albumin was also marginally higher after 6 months as compared to baseline (P = 0.07). The 
observed increase in C-reactive protein in the placebo group over 6 months was not apparent 
in the omega-3 group, although there was no significant difference between groups. Nuclear 
factor kappa B, malnutrition-inflammation score, normalized protein nitrogen appearance, body 
mass index, and hemoglobin were unaffected by the intervention.
Conclusion: “Directly observed treatment” with an omega-3 based supplement (as opposed 
to a pure protein supplement) showed beneficial effects on the lipid profile, and C-reactive pro-
tein levels. Further studies using a combination of outpatient and inpatient “directly observed 
  treatment” of omega-3 based supplementation is warranted.
Keywords: protein and omega-3 supplementation, inflammation, nutritional status, 
hemodialysis
Introduction
Cardiovascular disease (CVD) represents the major source of morbidity and is a 
l  eading cause of death in uremic patients on chronic hemodialysis.1 From   nontraditional 
CVD risk factors in dialysis patients, a malnutrition-inflammation complex syn-
drome (MICS) has been postulated to play a role in the etiology of premature CVD 
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in hemodialysis patients.2 Thus, there is considerable   interest 
in finding   appropriate interventions for the MICS in this 
population.
Protein energy malnutrition is highly prevalent in d  ialysis 
patients which negatively impacts prognosis. Protein energy 
malnutrition is implicated in a complex syndrome caused 
by nutritional and non-nutritional factors such as deficient 
food ingestion secondary to uremia, dietary restriction, 
chronic inflammatory state, and increased catabolism related 
to treatment modalities, nutrients loss in dialysate, and 
metabolic acidosis.3 Numerous studies have demonstrated 
that protein supplementation alone may improve protein 
metabolism and nutritional parameters and therefore improve 
clinical outcomes.4–6 Meanwhile, causes of inflammation 
are multifactorial including exposure of blood to dialyzer 
membranes or tubing, infection on vascular access, reduced 
antioxidants, and increased oxidative stress.3,7 Therefore, 
in order for a nutritional intervention to be most effective, 
it should be targeted at improving protein status and have 
anti-inflammatory properties.8
There is a growing scientific interest in the application of 
omega-3 fatty acids as a means to prevent CVD in dialysis 
patients. Omega-3 fatty acids have been postulated to reduce 
pro-inflammatory response, confer antithrombotic properties, 
improve lipid levels (particularly triglycerides), and improve 
endothelial function.9–12 To date, there is no well-established 
recommendation on omega-3 fatty acid supplementation in 
the dialysis population despite the fact that these patients 
have lower omega-3 intake13 and plasma levels.14 Some 
of the studies published used supraphysiological doses of 
omega-3 (.3 g/day) which required a high number of cap-
sules and may have been difficult to consume long term.15 
Moreover, there may be barriers to compliance with this 
type of nutritional intervention, especially when the study 
population includes non-Caucasian races, low income groups, 
and the unemployed.16 Some of the clinical studies relied 
only on subjective methods such as pill counting to measure 
compliance.17,18
Therefore, we performed a pilot study to investigate 
the technical feasibility of “directly observed treatment” 
of nutritional supplementation administered during 
regular dialysis sessions. Secondary outcomes included 
observations on nutritional and inflammatory status of 
hypoalbuminemic patients undergoing hemodialysis. We 
hypothesized that a combination of protein and omega-3 
supplementation would be more effective than protein 
supplementation alone in improving nutritional and 
i  nflammatory status.
Methods
Patients
Patients who were undergoing routine hemodialysis   treatment 
at the Great Lake Dialysis Clinic in Detroit, MI, were 
screened (n = 105). Selection criteria included serum albumin 
levels not meeting the outcome goal of the Kidney Disease 
Outcome Quality Initiative (KDOQI) guidelines19 (#3.9 g/
dL), age greater than 18 years, and ongoing dialysis treatment 
for at least 3 months prior to the study. Patients who were 
residents of nursing homes, receiving intradialytic parenteral 
nutrition or tube feeding, undergoing 8 hours of dialysis 
treatment, undergoing nocturnal dialysis, serum   albumin . 
3.9 g/dL, or who had fish allergies were excluded.
Study design and procedures
The present study was approved by the Human Ethics 
  Committee of Wayne State University and the Human Inves-
tigation Committee of Great Lakes Dialysis. Informed writ-
ten consent was obtained from all patients. Eligible subjects 
(n = 63) were randomized into two groups; placebo +   protein 
supplement (placebo, n = 32) and omega-3 + protein supple-
ment (omega-3, n = 31). Patients, care givers, and investiga-
tors were blinded from group assignments. The study lasted 
6 months.
Nutritional intervention and compliance
The nutritional intervention provided comprised two 
components. Both treatment groups received a blend of 
30 mL liquid protein supplement (Proteinex®; Llorens 
Pharmaceuticals Inc, Miami, FL) in 60 mL of apple juice 
providing 100 kcal, 18 g protein, and 8 g carbohydrate 
(specifically, 30 mL of Proteinex provides 18 g of   protein 
hydrolysate [72 kcals], with 1440 mg of L-arginine, 
540 mg of L-leucine, 420 mg of L-phenylalanine, 132 mg 
of   L-histidine, 780 mg of L-lysine, 360 mg of L-isoleu-
cine, 132 mg of L-methionine, and 66 mg of L-trypto-
phan).   Additionally, subjects were given four capsules of 
either omega-3 or placebo, formulated by Twin Rivers 
  Technologies (Quincy, MA). Each of the omega-3 cap-
sules contained 150 mg of docosahexaenoic acid (DHA) 
and 450 mg of eicosapentaenoic acid (EPA; total DHA 
600 mg, total EPA 1800 mg), while the other capsule was 
a placebo comprised of olive oil. Analysis of omega-3 and 
placebo capsules is presented in Table 1. Both protein and 
capsules were given to the patients three times a week 
after their regular dialysis session for a total duration of 
6 months. Compliance was ascertained by administering 
the supplements during the patients’ dialysis session with 
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close monitoring by nurses. Tolerability and side effects 
of supplements were recorded by registered nurses and 
hospitalization rates were also monitored.
Blood sampling and laboratory measures
The study flow chart is shown in Figure 1. Approximately 
20 mL of fasting blood sample was taken prior to the 
dialysis session. Plasma samples intended for lipid analysis 
were isolated from blood by centrifugation at 3000 rpm 
for 20 minutes at 4°C and were kept at 4°C to be analyzed 
on the following day. Blood samples for nuclear factor 
kappa B (NFκB) were processed immediately to obtain 
mononuclear cell extract using the Ficoll-Paque method20 
and the extract was kept at −80°C until further analysis. 
Serum samples for common renal profiles (serum   albumin, 
blood-urea-nitrogen, creatinine, hemoglobin) were sent 
to Satellite Laboratory Services (Redwood City, CA) for 
analysis and were measured using standard automated 
laboratory techniques.
Lipids analysis
Total cholesterol, high density lipoprotein (HDL) cholesterol, 
and triacylglycerol (TAG) in the plasma were determined 
by enzymatic reaction using kits purchased from Pointe 
Scientific Inc (Canton, MI). Low density lipoprotein (LDL) 
cholesterol was calculated using the Friedwald equation 
(LDL-C = total cholesterol minus HDL-C minus TAG/5). 
LDL-C to HDL-C ratio was calculated by dividing LDL-C 
by HDL-C values.
Inflammatory markers
Serum C-reactive protein (CRP) was analyzed by an inde-
pendent laboratory (DMC Laboratory, Detroit, MI) using an 
immunoturbidimetric method. Activated NFκB was measured 
from the nuclear extracts using a TransAm chemiluminescent 
(p65) kit purchased from Active Motif (Carlsbad, CA) using 
the procedure described by the manufacturer.
Nutritional indicators
Serum albumin was measured by the bromocresol green 
method using standard automated laboratory techniques. 
Normalized protein nitrogen appearance (nPNA) was 
calculated according to K/DOQI guidelines (2000).19 The 
malnutrition-inflammation score (MIS) questionnaire21 was 
also administered prior to (baseline), during (month 2) and at 
the end of the study (month 6). MIS is a quantitative scoring 
system that comprises ten components related to patients’ 
medical history, physical exam, body mass index (BMI), 
and laboratory parameters, which has been reported to be 
a useful tool to predict dialysis outcome, malnutrition, and 
inflammatory status.22–24 MIS was performed and calculated 
by a single person, a registered dietitian, to minimize inter-
observer variability.
Statistical analysis
The minimum sample size for each group was n = 31, which 
was estimated at a power of 80% and α = 0.05 for a two-
arm parallel study to detect a 0.2 g/dL difference in serum 
albumin. Results were analyzed using intention to treat. All 
study participants were maintained in the treatment groups to 
which they were randomized regardless of post randomiza-
tion withdrawal and any missing values reported accordingly. 
Categorical data are reported as number and percentage, 
while continuous data are reported as mean ± standard devia-
tion (SD) or as otherwise stated. Independent t-test was used 
to determine differences in the variables of interest between 
the two groups at baseline. The difference between baseline 
and month 2 and between baseline and month 6 for each 
group were tested using a paired t-test. Data that were not 
normally distributed were tested using a nonparametric test. 
Statistical significance was set at α = 0.05. All statistical tests 
were performed using SPSS (v 16.0; IBM, Chicago, IL). As 
there was no significant difference between baseline and the 
2-month values in any of the parameters measured, these are 
not discussed further (data not shown).
Table 1 Selected fatty acid composition of omega-3 and placebo 
capsule
Omega-3  
(g/100 g as FA)
Placebo  
(g/100 g as FA)
C16:0 0.96 13.86
C16:1 0.35 1.44
C17:0 0.14 0.07
C17:1 – 0.11
C18:0 4.66 2.73
C18:1n9 8.88 66.64
C18:2n6 2.00 11.42
C18:3n3 0.77 0.69
C20:0 0.50 0.43
C20:1n9 – 0.26
C20:5n3 35.36 –
C21:5n3 1.70 –
C22:5n3 4.95 –
C22:6n3 24.31 –
SAFA 7.02 17.26
MUFA 15.21 70.63
PUFA 77.77 12.11
Omega-3 67.08 0.69
Abbreviations: FA, fatty acids; SAFA, saturated fatty acids; MUFA, monounsaturated 
fatty acids; PUFA, polyunsaturated fatty acids.
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Results
Demographic profiles
The inclusion criteria were met by 69 patients and 
63 agreed to participate. Subjects were randomized based 
on albumin levels, and with the exception of gender 
distribution, there were no significant differences in age, 
duration on dialysis, BMI, and prevalence of existing 
comorbidity (diabetes mellitus) or indicators of d  ialysis 
adequacy (Kt/v) between the two groups (Table 2). 
The study population was homogenously comprised of 
A  frican-American ethnicities with no   difference in income 
between groups.
Tolerability, side effects, and compliance
Over the course of the study, four patients died due to (a) 
cerebrovascular accident (placebo group, n = 1), (b) diabetic 
infection (omega-3 group, n = 1) and (c) CVD (one patient 
from each group). There were no other adverse events 
reported (ie, a life-threatening adverse effect, inpatient 
hospitalization or prolongation of existing hospitalization, 
or a persistent or significant disability/incapacity), over 
the course of the study. No discernible “fishy” smells were 
reported by any of the patients with regards to capsule 
assignment. Two patients complained they could not swal-
low the pills (placebo group) and withdrew from the study 
(Figure 1). Twenty-one patients (33%) were able to take 
100% of the supplements provided during the 6-month study 
period. Sixty-seven percent of the patients (n = 22 in the 
omega-3 group and n = 21 in the placebo group) were able 
to take greater than 80% of the supplements. The principal 
reason for lack of compliance was subjects who missed their 
scheduled dialysis sessions.
Assessed for eligibility 
(n = 105) 
Randomization 
(n = 63) 
Excluded (n = 42) 
− Did not met exclusion
   criteria (n = 36)                                
− Declined to participate
   (n = 6)  
Allocated to omega-3 
group
(n = 31) 
Allocated to placebo 
group
(n = 32) 
Baseline: blood 
collection, MIS, 
anthropometric data 
Month-2: blood 
collection, MIS, 
anthropometric data 
Month-6: blood 
collection, MIS, 
anthropometric data
Analyzed  
(including drop out) 
(n = 28) 
Analyzed 
(including drop out) 
(n = 28) 
Voluntary drop-out  
(unable to swallow the capsule) 
(n = 2) 
Died
(n = 2) 
Died
(n = 2) 
Figure 1 Study’s flow chart.
Notes: All patients at the Great Lake Dialysis clinic (n = 105) were screened for eligibility. Sixty-nine patients met the inclusion criteria but six of them declined to participate. 
The remaining 63 patients were randomized into omega-3 and placebo groups and underwent intervention for 6 months. Seven additional subjects (placebo, n = 4; omega-3, 
n = 3) were excluded from data analysis due to death (n = 4, 2 from each group) or hospitalization (n = 3). Two patients voluntarily dropped out as they were unable to 
swallow the capsules but their data were included in the analysis (intent to treat).
Abbreviation: MIS, malnutrition-inflammation score.
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Effects on lipid profiles
One subject was excluded from the analysis due to high 
TAG levels (478 mg/dL) as the Friedwald equation for 
LDL-C estimation is not reliable when TAG levels exceed 
400 mg/dL.25 Total cholesterol was significantly reduced 
over the 6 months intervention in both groups (P , 0.001; 
Table 3). At the end of 6 months, the reduction in total 
cholesterol in the   omega-3 group (−37 ± 32 mg/dL) was 
approximately 50% greater than the reduction seen in the 
placebo group (−21 ± 26 mg/dL, P = 0.057). While HDL-C 
levels were increased at month-6 compared to baseline in 
both groups (t = −4.077, P = 0.000 and t = −3.410, P = 0.004, 
respectively), there was no significant difference between 
groups (P = 0.531). LDL-C was reduced in both groups 
  (omega-3 group: t = 6.083, P = 0.000, placebo group: 
t = 4.200, P = 0.000) at month-6 compared to baseline, how-
ever, no significant differences between the two groups were 
noted at the end of the study (P = 0.092). The LDL-C/HDL-C 
ratios were significantly improved in both groups compared to 
baseline (omega-3 group: t = 5.875, P = 0.000, placebo group: 
t = 4.683, P = 0.000). After 6 months, the omega-3 group 
had a significantly larger reduction in LDL-C/HDL-C ratio 
compared to the placebo group (−1.3 ± 1.1 versus −0.7 ± 0.8, 
P = 0.043). Compared to baseline, TAG levels did not change 
significantly in the placebo group (P = 0.561), while there was 
a tendency for a decline in the omega-3 group (P = 0.064).
Effects on nutritional parameters
Serum albumin and other nutritional indices are presented 
in Table 4. Serum albumin at the end of the study was 
comparable to the values observed at baseline in both the 
omega-3 (t = −1.895, P = 0.070) and placebo (t = −0.314, 
P = 0.756) groups. Comparison between both groups showed 
no significant difference (P = 0.295). Similarly, no changes 
were observed in MIS score, nPNA, and BMI following the 
intervention within or between the groups. Additionally, 
hemoglobin levels were not changed following intervention 
in both groups (omega-3 group: t = 1.100, P = 0.282, placebo 
group: t = −0.731, P = 0.471).
Effects on inflammatory indicators
The NFκB levels observed after 6 months in the omega-3 
and placebo groups were similar to baseline values (Table 5). 
Additionally, mean differences (month-6 minus baseline) 
between omega-3 and placebo groups were not signifi-
cantly different (P = 0.134). With regards to CRP levels, 
mean values showed a significant elevation in the placebo 
Table 2 Clinical and demographic characteristics of the study 
population
Omega-3  
(n = 31)
Placebo  
(n = 32)
P-value
Demographics
Age (years) 59 ± 13 58 ± 13 0.845
Ethnicity
  African American (n, %) 30 (97) 32 (100) –
  Caucasian (n, %) 1 (3) 0 (0) –
Gender (males, %) 20 (62.5) 12 (38.7) 0.059
Income ($ per month) 1015 ± 576 1148 ± 761 0.552
Clinical
Time on dialysis (years) 3.6 ± 2.9 3.3 ± 3.8 0.784
BMI (kg/m2) 28.4 ± 8.3 26.9 ± 7.8 0.468
Diabetes mellitus (n, %) 20 (62.5) 20 (64.5) 0.868
Kt/v 1.58 ± 0.29 1.63 ± 0.32 0.536
Statin usage (n, %) 11 (35.5) 9 (28.1) 0.530
CRP (mg/dL) 5.8 ± 9.2 4.9 ± 5.6 0.134
Notes: Differences in age, time on dialysis, BMI, Kt/v and income were tested using 
independent t-test. Baseline CRP levels are reported in median ± interquartile range. 
Differences were tested using Mann–Whitney rank-sum test. Differences in gender, 
diabetes mellitus, and statin treatment were tested using chi-square. P , 0.05 is 
considered significant.
Abbreviations:  BMI,  body  mass  index;  Kt/v,  index  of  dialysis  adequacy;  CRP,   
C-reactive protein.
Table 3 Means and standard deviations of lipid profiles (TC, HDLC, LDLC, and TAG) at baseline and month-6
Placebo (n = 26) Omega-3 (n = 28) P overall
Baseline Month-6 Diff P Baseline Month-6 Diff P
Lipid profiles
TC (mg/dL) 159 ± 49 138 ± 42  -21 ± 26 0.000 176 ± 36 139 ± 29  -37 ± 32 0.000 0.057
HDLC (mg/dL)   44 ± 13   49 ± 11    +5 ± 8 0.004   41 ± 14   47 ± 16    +6 ± 8 0.000 0.531
LDLC (mg/dL)   94 ± 42   69 ± 35  -25 ± 27 0.000 108 ± 34   71 ± 29  -39 ± 33 0.000 0.092
TAG (mg/dL) 104 ± 69   96 ± 68    -7 ± 61 0.561 123 ± 60 102 ± 53  -20 ± 55 0.064 0.405
LDL-HDL ratio  2.2 ± 1.0  1.5 ± 0.9 -0.7 ± 0.8 0.000  3.0 ± 1.6  1.7 ± 1.0 -1.3 ± 1.1 0.000 0.043
Notes: All values are presented as mean ± SD. P values for each group derived from paired t-test between baseline versus month-6 comparison. Overall P values derived 
using independent t-test, tested for mean differences of lipid profiles parameters between omega-3 and placebo groups (bold face). Data excludes values from 7 subjects 
(placebo, n = 4; omega-3, n = 3) who died (n = 4, 2 from each group), or were hospitalized (n = 3), during the course of the study. One subject (placebo) was excluded due 
to extremely high TAG levels (478 mg/dL) as the Friedwald equation is not reliable when TAG levels exceed 400 mg/dL.
Abbreviations: TC, total cholesterol; HDLC, high density lipoprotein cholesterol; LDLC, low density lipoprotein cholesterol; TAG, triacylglycerides; Diff, mean difference 
of month-6 minus baseline.
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group (t = −2.158, P = 0.040) but not the omega-3 group 
(t = −0.582, P = 0.565) over 6 months. However these dif-
ferences were not apparent when median CRP values were 
compared. Additionally, there was a significant inverse 
association between CRP and albumin levels across both 
groups (r = −0.261, P = 0.049).
Discussion
Our study tested the potential of a combination of protein 
and omega-3 supplementation to improve nutritional and 
inflammatory markers in chronic hemodialysis patients. To 
increase compliance the supplements were administered 
  during patients’ routine dialysis session, three times per week 
(“directly observed treatment”). Directly observed treat-
ment allowed for two-thirds of the subjects to receive more 
than 80% of the stated overall dose over a 6-month period. 
While compliance was excellent in patients who came in for 
regular dialysis sessions, the significant comorbidities within 
this patient population resulted in a large number of missed 
dialysis treatments (and hence missed supplementation).
We observed that serum albumin, one of the markers of 
nutritional status, was not improved significantly in either 
group following the intervention. This finding was in   contrast 
to what has been reported in previous studies.4–6 This may be 
explained by the fact that only a small number of patients 
were able to take all of the supplements provided to them 
(no missing days) during the study course (n = 21, 33.3%). 
Patients missed days of supplementation mostly due to 
frequent hospitalization or because they failed to show up 
for their routine dialysis treatment, ranging from 1–44 days. 
Therefore, this could potentially upset the effect of omega-3 
and protein supplementation per se. Further analysis on a pool 
of patients who substantially completed the supplementation 
course (ie, taking .80% of the supplements) showed mar-
ginal improvement in serum albumin at month-6 compared to 
baseline (3.6 ± 0.3 g/dL versus 3.7 ± 0.3 g/dL, P = 0.079) but 
no improvements were noted in those who took ,80% of the 
supplements (3.7 ± 0.2 vs 3.7 ± 0.4, P = 0.939). Interestingly, 
nPNA , an indicator of protein intake, remained constant in 
both groups despite protein supplementation. A similar study 
by Moretti et al26 also noted a similar trend, in which there 
were no changes in nPCR despite improvement in serum 
albumin in the protein group for the second 6 months.
Reduced protein intake and an increase in inflammatory 
response are two important factors that lead to a decrease 
in serum albumin.27 However, Kaysen et al28 had noted that 
low serum albumin in dialysis patients may be attributed to 
systemic inflammation rather than nutritional inadequacy 
Table 4   Means  and  standard  deviations  of  nutritional  status  indicators  (Ser  alb,  Hgb,  MIS  score,  nPNA,  and  BMI)  at  baseline 
and month-6
Placebo (n = 27) Omega-3 (n = 28) P overall
Baseline Month-6 Diff P Baseline Month-6 Diff P
Nutritional status
Ser alb (g/dL)   3.7 ± 0.2   3.8 ± 0.4   0.0 ± 0.3 0.756   3.6 ± 0.3   3.7 ± 0.3   0.1 ± 0.3 0.070 0.295
Hgb (g/L) 11.0 ± 1.0 11.3 ± 1.7   0.2 ± 1.7 0.471 10.4 ± 1.1   10.8 ± 1.5   0.3 ± 1.4 0.282 0.866
MIS score   7.6 ± 3.6   8.1 ± 4.0   0.6 ± 4.0 0.215   9.0 ± 3.6   9.1 ± 3.4   0.4 ± 2.2 0.408 0.730
nPNA 0.96 ± 0.38 0.91 ± 0.22 -0.01 ± 0.23 0.810 0.99 ± 0.29 0.87 ± 0.25 -0.07 ± 0.45 0.471 0.598
BMI (kg/m2) 25.4 ± 5.6 25.1 ± 6.1   0.3 ± 1.8 0.327 28.1 ± 7.0 28.1 ± 7.2   0.1 ± 1.0 0.699 0.500
Notes: All values are presented as mean ± SD. P values for each group derived from paired t-test between baseline versus month-6 comparison. Overall P values derived using 
independent t-test, tested for mean differences of nutritional parameters between omega-3 and placebo groups (bold face). Data excludes values from 7 subjects (placebo, n 
= 4; omega-3, n = 3) who died (n = 4, 2 from each group) or were hospitalized (n = 3), during the course of the study.
Abbreviations: Ser alb, serum albumin; Hgb, hemoglobin; MIS, malnutrition inflammation score; nPNA, normalized protein equivalence of nitrogen appearance; BMI, body 
mass index; Diff, mean difference of month-6 minus baseline.
Table 5 Means and standard deviations of inflammatory indicators (NFκB, CRP) at baseline and month-6
Placebo (n = 27) Omega-3 (n = 28) P overall
Baseline Month-6 P Baseline Month-6 P
NFκB (μg/mL) 2.48 ± 1.03 2.54 ± 1.14 0.703 2.52 ± 1.19 2.15 ± 0.4 0.129 0.134
CRP (mg/dL)*   6.6 ± 8.3 11.0 ± 13.9 0.040 13.1 ± 17.5 14.6 ± 19.7 0.565 0.259
CRP (mg/dL)**   4.9 ± 5.6   4.6 ± 12.0 0.034   5.8 ± 9.2   6.1 ± 14.0 0.412 0.326
Notes: NFκB value is presented as mean ± SD. CRP value is presented as *mean ± SD and **median ± IQR. P values for each group derived from either paired t-test 
(NFκB )/Wilcoxon rank sum test (CRP) between baseline versus month-6 comparison. Overall P values derived using either independent t-test/Mann–Whitney rank sum test, 
tested for mean differences of inflammatory parameters between omega-3 and placebo groups (bold face). Data excludes values from 7 subjects (placebo, n = 4; omega-3,   
n = 3) who died (n = 4, 2 from each group) or were hospitalized (n = 3), during the course of the study.
Abbreviations: NFκB, Nuclear factor kappa-light-chain enhancer of activated B cells; CRP, C-reactive protein.
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as a causative factor per se. In relation to this, we also 
observed a significant inverse correlation between serum 
albumin and CRP which may indicate the influence of an 
inflammatory process on serum albumin levels. Friedman 
and Fadem29 suggested that serum albumin should be taken 
as a marker of illnesses rather than nutrition. This is due to 
the fact that serum albumin has a strong ability to predict 
mortality but rather limited prediction for nutritional status 
due to significant influence of non-nutrition causes (such as 
inflammation).
Many of the omega-3 fatty acid supplementation stud-
ies in dialysis patients have described various potential 
outcomes such as attenuating dyslipidemia, inflammation, 
and providing a cardioprotective effect. Moreover, there is 
substantial evidence for reducing TAG levels30–32 even at a 
dosage as low as 1.5 g/day.33 As for plasma TAG, we saw 
a tendency for a reduction in TAG levels in both groups 
although in the omega-3 group statistical significance 
was marginal (P = 0.064). The large variation in the dif-
ference in TAG changes observed in the placebo group 
(−7 ± 61 mg/dL, P = 0.56, Table 3) could be attributed 
to one subject with very high triglyceride concentrations. 
Upon removal of this subject the difference in TAG levels 
between the 6-month and baseline value was 1 ± 44 mg/dL, 
P = 0.89. Thus collectively these data suggest no change 
in TAG levels over 6 months in the placebo group, while 
there was a tendency for a reduction in TAG levels in the 
omega-3 group (–20 ± 44 mg/dL, P = 0.064).   Previous 
studies18,34 which administered a higher amount of omega-3 
per week, with varying percentages of EPA/DHA but with 
a shorter duration (4–8 weeks), also reported no changes 
in TAG levels.   However, Bouzidi et al reported that a 
supplementation of 2.1 g omega-3 daily for 3 months 
among chronic kidney disease patients reduced TAG levels 
by 48%.35 However, it is important to note that the base-
line TAG levels in their study were much higher than the 
current study (275 ± 58 mg/dL versus 123 ± 60 mg/dL in 
the omega-3 group). We postulate that, the baseline TAG 
levels (omega-3 group: 123 ± 60 mg/dL; placebo group: 
104 ± 69 mg/dL) were within the normal levels and thus 
may not have been sufficiently elevated to achieve a sig-
nificant reduction. Skulas-Ray et al reported that the extent 
of TAG lowering with omega-3 is a function of baseline 
TAG levels.36 Omega-3 supplementation resulted in better 
improvement in LDL-C/HDL-C ratios as compared to pla-
cebo which appeared to be due to a greater improvement in 
non-HDL-C. As for inflammatory markers, our results for 
CRP were inconclusive. While mean values in the placebo 
group increased over the 6-month period, this was not the 
case in the omega-3 group, in which CRP levels stayed the 
same. Thus omega-3, if not effective in attenuating inflam-
mation, may be beneficial in preventing further increases in 
inflammatory status. However when the data were evaluated 
using median CRP values, these differences were no longer 
apparent suggesting the need for a larger sample size to 
definitively resolve this issue. Only a small number of stud-
ies have investigated the effects of omega-3 on inflammatory 
markers in hemodialysis patients. It is important to note that 
most of these studies are not comparable due to differences 
in study design, supplement dosage, EPA/DHA ratios and 
study duration. Saifullah et al showed that a supplementa-
tion of 1.3 g of oral EPA and DHA daily over a period of 
3 months could modestly reduce CRP levels.37 However, a 
recent study using a larger dosage (2.08 g/day) but a shorter 
duration (10 weeks) showed no effects on serum systemic 
inflammatory markers (CRP, interleukin-6, tumor necrosis 
factor-α) and oxidative stress (malondialdehyde, total anti-
oxidant capacity).38 In a prospective cohort study by Noori 
et al, the authors showed that a lower omega-6 to omega-3 
ratio (∼6) was associated with decreased inflammation and 
overall mortality in hemodialysis patients which indicates 
the importance of n-6/3 polyunsaturated fatty acid ratios in 
the diet.13 However, our study was not designed to investigate 
the effects of this ratio per se.
NFκB, a key player in pathogenesis of inflammation, is 
stimulated by pro-inflammatory agents such as cytokines 
and CRP. Studies have shown that NFκB activation and 
subsequent activation of mononuclear cells triggers a process 
that causes myocardial inflammatory damage in hemodialysis 
patients.39,40 Interestingly, our data for translocation of acti-
vated NFκB to the nucleus showed no significant changes 
following the intervention within and between both groups 
even though we saw an increase in CRP levels in the placebo 
group. The latter may have been due to the fact that the 
baseline CRP values in the placebo group were lower than 
those assigned to the omega-3 group.
Study limitations
We were restricted in our patient population to one dialysis 
clinic for this pilot study. While the lipid data suggested 
benefits of omega-3, the data for inflammatory markers was 
less clear cut. One plausible explanation for variation in 
inflammatory markers in the current study may be related to 
insufficient dosage/frequency of omega-3 s  upplementation 
as well as compliance (due to frequent hospitaliza-
tion resulting in subjects missing dialysis sessions and 
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therefore   supplementation). There are several similar studies 
which also failed to report significant changes in inflamma-
tory markers.18,41–43 Studies which demonstrated a significant 
effect of omega-3 supplementation on inflammation indices 
are those with a higher dosage and more frequent administra-
tion of the supplement (9.1 to 21 g/week versus 7.2 g/week 
DHA + EPA in the current study) as well as reported higher 
patient compliance.17,44–46 Another factor that could poten-
tially explain the contradictory finding in our study with 
those studies is baseline levels of inflammatory markers. 
Omega-3 supplementation appears to be more effective in 
studies reporting higher baseline CRP (.13.8 mg/dL) than 
those that did not.17,38,44
Notwithstanding some of the limitations discussed 
above, ours is one of the few studies to report on the 
use of “directly observed treatment” of oral nutritional 
supplementation with protein and omega-3 in a cohort of 
hemodialysis patients. Our results suggest that “directly 
observed treatment” is technically feasible in hemodialysis 
patients and does not disrupt the normal dialysis schedule. 
The relatively large number of missed dialysis sessions 
due to hospitalizations, however, suggests that “directly 
observed treatment” should be used in the setting of both 
outpatient and inpatient dialysis sessions in order to opti-
mize   compliance. In addition, while emphasizing the huge 
progressive inflammatory burden in hemodialysis patients 
over time; this pilot study suggests that “directly observed 
treatment” with a combination of omega-3 and protein-
based supplement (as opposed to a pure protein supplement) 
could have some beneficial effects on lipid profile and CRP 
progression. Further studies using a combination of outpa-
tient and inpatient “directly observed treatment” of fish oil 
based nutritional supplementation are warranted.
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